The implantable, single-use 9526 Reveal Plus Insertable Loop Recorder can record EKGs in patients with cardiac arrhythmia. It's ferromagnetic components present no safety risk, but patients must be well-informed.
The 9526 Reveal Plus Insertable Loop Recorder (ILR, Medtronic, Minneapolis) is an implantable single-use programmable device containing two surface electrodes for continuous recording of the patient's subcutaneous electrocardiogram.
This device is indicated for patients who experience transient symptoms that may suggest a cardiac arrhythmia and for patients with clinical syndromes or situations that put them at increased risk of cardiac arrhythmias. Implanting the ILR takes about 15 to 20 minutes and can be done under local anesthetic in an outpatient setting. The physician makes an incision about 2 cm in length, creating a pocket the same size and shape as the ILR device. Once the device is inserted in the subcutaneous pocket, it is programmed to record the ECG. Because the ILR is capable of recording an ECG during an actual fainting episode, physicians are able to confirm or rule out an abnormal heart rhythm more definitively. Since this device may be used continuously for up to 14 months, the likelihood of capturing heart rhythm information during an infrequent fainting episode is excellent.
The Reveal Plus ILR contains no lead wires or large loops of electrically conductive material. The electromagnetic fields produced during MR imaging may adversely affect the data stored by the ILR, however. Before permitting a patient with this device into the MR environment, consideration must be given to interrogating the ILR in order to save the data that could become corrupted or erased as a result of undergoing an MR imaging procedure. Careful planning in conjunction with the physician responsible for the patient's ILR is necessary.
Also, since the ILR contains ferromagnetic components, strong magnetic fields associated with the MR system will exhibit mechanical force on the ILR. The patient may feel slight movement of the ILR. While this does not represent a safety hazard, the patient must be informed of this possibility to avoid undue concern. Additional MRI-related information may be found in the "Reveal Plus 9526 Insertable Loop Recorder System Product Information Manual":
Information provided with permission, Medtronic, Minneapolis, http://www.medtronic.com/reveal/rpmri.html. Dr. Shellock is an adjunct clinical professor of radiology at Keck School of Medicine, University of Southern California, and Institute for Magnetic Resonance Safety, Education, and Research.
Krahn A, Klein G, Yee R, Norris C. Final results from a pilot study with an implantable loop recorder to determine the etiology of syncope in patients with negative non-invasive and invasive testing. Am J Cardiol 1998;82:117-119. Reveal Syncope Validation Project (RSVP) Clinical Summary. Medtronic data on file. Shellock FG, Tkach JA, Ruggieri PM, Masaryk TJ. Cardiac pacemakers, ICDs, and loop recorder: evaluation of translational attraction using conventional ("long-bore") and "short-bore" MR systems at 1.5- and 3-Tesla. J Cardiovasc Magn Reson 2003;5:387-397.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).